For example, pre-clinical and clinical leukemia studies have demonstrated the superior anti-tumor activity and long-term persistence of less-differentiated CD19-CAR T cell products with a high frequency of naïve and central memory T cell subsets [12,13,14,15]. This evidence concerns the gene CD19 and neoplasm.